You are here

Article Text

Article menu
Download PDFPDF
Ad watch
‘Flavour ban approved’: new marketing strategies from tobacco-free nicotine pouch maker Zyn
  1. Alayna P Tackett,
  2. Jessica L Barrington-Trimis,
  3. Adam M Leventhal
  1. Department of Population and Public Health Sciences, University of Southern California Keck School of Medicine, Los Angeles, California, USA
  1. Correspondence to Dr Alayna P Tackett, Department of Population and Public Health Sciences, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA; alayna.tackett{at}usc.edu

https://doi.org/10.1136/tobaccocontrol-2021-057222

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Tobacco-free oral nicotine pouches—sachets containing microcrystalline cellulose with nicotine salt, flavours, sweeteners and other additives placed in between the lip and gums—are increasingly marketed and sold in the USA.1 The most widely sold tobacco-free oral nicotine product in the USA is Zyn,1 made by Swedish Match. According to the company’s latest investor report,2 Zyn shipments grew by more than 40% from 2020 to 2021, with sales of individual cans increasing from 83.2 million cans in 2020 to 125.7 million cans in 2021.2

    As of 9 December 2021, the US Zyn public website displayed an advertisement indicating two Zyn products are ‘flavour ban approved’ (figure 1). ‘Smooth’ Zyn was described as ‘an unflavoured experience for pure nicotine enjoyment.’ ‘Chill’ Zyn was described as ‘a refreshing unflavoured nicotine experience’ (figure 2). Both are labelled ‘unflavoured’, which raises a question as to what constitutes a flavoured or unflavoured tobacco or …

    View Full Text

    Footnotes

    • Contributors APT designed, wrote and revised the manuscript. JB-T and AL participated substantively in design and editing of the final manuscript.

    • Funding Research reported in this publication was supported by the National Cancer Institute and the FDA Centre for Tobacco Products (CTP) under award number U54CA180905, National Cancer Institute under award number R01CA229617, National Institute on Drug Abuse under award number K24DA048160, and the National Heart, Lung and Blood Institute (K01HL148907).

    • Disclaimer The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the FDA.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.